1
Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses B I Goddard: ARPE-19 as a platform cell line for encapsulated cell-based delivery. Neurotech, Ivor R Elrifi Esq, Christina V Karnakis Esq, Mintz Levin Cohn Ferris Glovsky and Popeo PC, March 26, 2002: US06361771 (32 worldwide citation)

ARPE-19 cells were evaluated as a platform cell line for encapsulated and un-encapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modif ...


2
Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses B I Goddard: ARPE-19 as a platform cell line for encapsulated cell-based delivery. Neurotech, Mintz Levin Cohn Ferris Glovsky and Popeo P C, Ivor R Elrifi, Christina K Stock, October 3, 2006: US07115257 (15 worldwide citation)

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modifi ...


3
Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses BI Goddard: ARPE-19 as platform cell line for encapsulated cell-based delivery. Mintz Levin Cohn Ferris Glovsky, And Popeo PC, March 29, 2007: US20070071734-A1

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modifi ...


4
Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses BI Goddard: ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery. Neurotech Usa, Mintz Levin Cohn Ferris Glovsky And Popeo PC, October 29, 2009: US20090269389-A1

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modifi ...


5
Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses BI Goddard: ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery. Neurotech Usa, Mintz Levin Cohn Ferris Glovsky And Popeo PC, October 29, 2009: US20090269319-A1

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modifi ...